Ultrasound-Guided Percutaneous Ethanol Ablation for the Management of Recurrent Thyroid Cancer: Evaluation of Efficacy and Impact on Disease Course
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Objectives: Neck recurrences of thyroid cancer are frequently detected in routine ultrasound (US)follow-up. Broad management of these lesions may include active surveillance, surgery or local percutaneoustechniques, but for the latter, little is known about impact on long-term follow-up and need of subsequentradioactive iodine (RAI) therapy. Materials and Methods: 42 patients underwent US-guided ethanol ablation (EA)over 71 thyroid bed or lymph node confirmed recurrences. All volume reduction ＞50%, absence of power Dopplersignal and fine needle aspiration (FNA) washout thyroglobulin (Tg) value ＜1 ng/mL should be present to considera complete ablation. Patients with TNM stage I-II, ≤2 lesions and/or baseline plasma TSH-suppressed Tg level ＜0.2ng/mL did not undergo post-EA RAI therapy. Post-EA plasma Tg values were compared to baseline in patientswith and without subsequent RAI therapy. Results: 62 lesions (87.32%) achieved a complete ablation after a meanfollow-up of 40.5 months (range, 12-73). Four treated lesions (5.63%) recurred (3/39 and 1/32 in patients withand without subsequent RAI therapy), and 7 patients (16.66%) developed new recurrences throughout follow-up(5/19 and 2/23 with and without RAI therapy). Both plasma TSH-suppressed and TSH-stimulated Tg levelsdescended after EA in both groups, and 17/38 (44.73%) patients achieved a TSH-suppressed Tg ＜0.2 ng/mL,with no differences between both groups of patients. All EA procedures were conducted safely without seriousor persistent side effects. Conclusion: Successful EA were achieved safely in 87.32% of patients with recurrentthyroid cancer, with a positive effect on systemic disease as reflected by plasma post-EA Tg levels. A subset ofpatients with TNM stage III, ≤2 lesions and/or low pre-EA plasma Tg levels may not need subsequent RAI therapyafter successful ablation. Overall, EA is an effective and balanced therapy for selected patients with neck recurrentthyroid cancer as an alternative to surgery.
Abstract
Background and Objectives: Neck recurrences of thyroid cancer are frequently detected in routine ultrasound (US)follow-up. Broad management of these lesions may include active surveillance, surgery or local percutaneoustechniques, but for the latter, little is known about impact on long-term follow-up and need of subsequentradioactive iodine (RAI) therapy. Materials and Methods: 42 patients underwent US-guided ethanol ablation (EA)over 71 thyroid bed or lymph node confirmed recurrences. All volume reduction ＞50%, absence of power Dopplersignal and fine needle aspiration (FNA) washout thyroglobulin (Tg) value ＜1 ng/mL should be present to considera complete ablation. Patients with TNM stage I-II, ≤2 lesions and/or baseline plasma TSH-suppressed Tg level ＜0.2ng/mL did not undergo post-EA RAI therapy. Post-EA plasma Tg values were compared to baseline in patientswith and without subsequent RAI therapy. Results: 62 lesions (87.32%) achieved a complete ablation after a meanfollow-up of 40.5 months (range, 12-73). Four treated lesions (5.63%) recurred (3/39 and 1/32 in patients withand without subsequent RAI therapy), and 7 patients (16.66%) developed new recurrences throughout follow-up(5/19 and 2/23 with and without RAI therapy). Both plasma TSH-suppressed and TSH-stimulated Tg levelsdescended after EA in both groups, and 17/38 (44.73%) patients achieved a TSH-suppressed Tg ＜0.2 ng/mL,with no differences between both groups of patients. All EA procedures were conducted safely without seriousor persistent side effects. Conclusion: Successful EA were achieved safely in 87.32% of patients with recurrentthyroid cancer, with a positive effect on systemic disease as reflected by plasma post-EA Tg levels. A subset ofpatients with TNM stage III, ≤2 lesions and/or low pre-EA plasma Tg levels may not need subsequent RAI therapyafter successful ablation. Overall, EA is an effective and balanced therapy for selected patients with neck recurrentthyroid cancer as an alternative to surgery.
참고문헌 (41)
- Greenlee RT, "Cancer statistics, 2001", CA Cancer J Clin, 51(1), pp.15~36 (2001)
- Sherman SI, "Thyroid carcinoma", Lancet, 361(9356), pp.501~511 (2003)
- Guth S, "Very high prevalence of thyroid nodules detected by high frequency(13 MHz)ultrasound examination", Eur J Clin Invest, 39(8), pp.699~706 (2009)
- Leenhardt L, "Advances in diagnostic practices affect thyroid cancer incidence in France", Eur J Endocrinol, 150(2), pp.133~139 (2004)
- Davies L, "Current thyroid cancer trends in the United States", JAMA Otolaryngol Head Neck Surg, 140(4), pp.317~322 (2014)
- Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer", Thyroid, 26(1), pp.1~133 (2016)
- Benbassat CA, "Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer", World J Surg, 30(6), pp.1088~1095 (2006)
- Schmidbauer B, "Differentiated thyroid cancer-treatment : state of the art", Int J Mol Sci, 18(6), pp.1292~ (2017)
- Aschebrook-Kilfoy B, "The clinical and economic burden of a sustained increase in thyroid cancer incidence", Cancer Epidemiol Biomarkers Prev, 22(7), pp.1252~1259 (2013)
- Cady B, "An expanded view of risk-group definition in differentiated thyroid carcinoma", Surgery, 104(6), pp.947~953 (1988)
- Hay ID, "Predicting outcome in papillary thyroid carcinoma : development of a reliable prognostic scoring system in a cohort of 1779patients surgically treated at one institution during 1940 through 1989", Surgery, 114(6), pp.1050~1057 (1993)
- Uchida H, "Long-term results of surgery for papillary thyroid carcinoma with local recurrence", Surg Today, 43(8), pp.848~853 (2013)
- Roh JL, "Central compartment reoperation for recurrent", persistent differentiated thyroid cancer : patterns of recurrence, morbidity, and prediction of postoperative hypocalcemia, 2011, pp.18(5), 1312~1318
- Samaan NA, "The results of various modalities of treatment of well differentiated thyroid carcinomas : a retrospective review of 1599 patients", J Clin Endocrinol Metab, 75(3), pp.714~720 (1992)
- Al-Saif O, "Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer", J Clin Endocrinol Metab, 95(5), pp.2187~2194 (2010)
- Schuff KG, "Management of recurrent", persistent papillary thyroid carcinoma : efficacy of the surgical option, 2011, pp.96(7), 2038~2039
- Yim JH, "The outcomes of first reoperation for locoregionally recurrent", persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation, 2011, pp.96(7), 2049~2056
- Torlontano M, "Follow-up of low risk patients with papillary thyroid cancer : role of neck ultrasonography in detecting lymph node metastases", J Clin Endocrinol Metab, 89(7), pp.3402~3407 (2004)
- 김원배, "A Closer Look at Papillary Thyroid Carcinoma Won Bae", Endocrinology and Metabolism, 30(1), pp.1~6 (2015), 대한내분비학회
- Lewis BD, "Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma", AJR Am J Roentgenol, 178(3), pp.699~704 (2002)
- Heilo A, "Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma", J Clin Endocrinol Metab, 96(9), pp.2750~2755 (2011)
- Hay ID, "Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected"recurrent"neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy", Surgery, 154(6), pp.1448~1454 (2013)
- Guenette JP, "Image-guided ablation of postsurgical locoregional recurrence of biopsy-proven welldifferentiated thyroid carcinoma", J Vasc Interv Radiol, 24(5), pp.672~679 (2013)
- Nixon IJ, "Image-guided chemical and thermal ablations for thyroid disease : review of efficacy and complications", Head Neck, 40(9), pp.2103~2115 (2018)
- Shin JE, "Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers : current status and challenges", Curr Opin Oncol, 25(1), pp.14~19 (2013)
- 이선진, "Radiofrequency Ablation to Treat Loco-Regional Recurrence of Well-Differentiated Thyroid Carcinoma", Korean Journal of Radiology, 15(6), pp.817~826 (2014), 대한영상의학회[DOI]
- Park KW, "Inoperable symptomatic recurrent thyroid cancers : preliminary result of radiofrequency ablation", Ann Surg Oncol, 18(9), pp.2564~2568 (2011)
- 김지훈, "2017 Thyroid Radiofrequency Ablation Guideline: Korean Society of Thyroid Radiology", Korean Journal of Radiology, 19(4), pp.632~655 (2018), 대한영상의학회[DOI]
- Garberoglio R, "Radiofrequency ablation for thyroid nodules : which indications? The first Italian opinion statement", J Ultrasound, 18(4), pp.423~430 (2015)
- Perrier ND, "Differentiated and anaplastic thyroid carcinoma : major changes in the American Joint Committee on Cancer eighth edition cancer staging manual", CA Cancer J Clin, 68(1), pp.55~63 (2018)
- Cunha N, "Thyroglobulin detection in fine-needle aspirates of cervical lymph nodes : a technique for the diagnosis of metastatic differentiated thyroid cancer", Eur J Endocrinol, 157(1), pp.101~107 (2007)
- Ahmed M, "Image-guided tumor ablation:standardization of terminology and reporting criteria--a 10-year update: supplement to the consensus document", J Vasc Interv Radiol, 25(11), pp.1706~1708 (2014)
- Mauri G, "Image-guided thyroid ablation : proposal for standardization of terminology and reporting criteria", Thyroid, 29(5), pp.611~618 (2019)
- Suh CH, "Efficacy and safety of radiofrequency and ethanol ablation for treating locally recurrent thyroid cancer : a systematic review and meta-analysis", Thyroid, 26(3), pp.420~428 (2016)
- Jeong SY, "Ethanol and thermal ablation for malignant thyroid tumours", Int J Hyperthermia, 33(8), pp.938~945 (2017)
- Kim SY, "Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer", Eur Arch Otorhinolaryngol, 274(9), pp.3497~3501 (2017)
- Monchik JM, "Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma", Ann Surg, 244(2), pp.296~304 (2006)
- Fontenot TE, "Percutaneous ethanol injection vs reoperation for locally recurrent papillary thyroid cancer : a systematic review and pooled analysis", JAMA Otolaryngol Head Neck Surg, 141(6), pp.512~518 (2015)
- Tomoda C, "Cervical lymph node metastases after thyroidectomy for papillary thyroid carcinoma usually remain stable for years", Thyroid, 26(12), pp.1706~1711 (2016)
- Gulcelik MA, "Radioguided occult lesion localization for locally recurrent thyroid carcinoma", Eur Arch Otorhinolaryngol, 274(7), pp.2915~2919 (2017)
- Borso E, "Radioguided occult lesion localization of cervical recurrences from differentiated thyroid cancer : technical feasibility and clinical results", Q J Nucl Med Mol Imaging, 57(4), pp.401~411 (2013)